- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
FDA accepted the company's response to the Complete Response Letter (CRL) for the drug CARDAMYST.
1 report, 1 independent
Updated Aug 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA accepted the company's response to the Complete Response Letter (CRL) for the drug CARDAMYST.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireMilestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update FDA Accepted the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Sp